Jemperli-Zejula combo meets primary endpoint in Phase III endometrial cancer trial
The late-stage trial assessed the combination against placebo plus chemotherapy followed by placebo and the combination met the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Dec 23
The late-stage trial assessed the combination against placebo plus chemotherapy followed by placebo and the combination met the…
14 Dec 23
The fourth generation BDTX-1535 is an oral, brain-penetrant, covalent EGFR inhibitor, which is currently in Phase 1 clinical…
13 Dec 23
The trial assessed Darzalex SC formulation-based quadruplet induction, consolidation regimen and doublet maintenance regimen in patients with transplant-eligible…
11 Dec 23
According to the results, 200mg twice daily iptacopan showed superiority against placebo in delivering clinically meaningful and statistically…
08 Dec 23
First global Phase 3 study to report positive results with an anti-CD38 therapy in combination with VRd in…
08 Dec 23
The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools…
07 Dec 23
IGC Pharma to Discuss AI Partnership and Initiatives at Biotech Showcase 2024
06 Dec 23
A comparison of the intent-to-treat population at eight years of follow-up with MONARCH 3 revealed that women taking…
06 Dec 23
The trial achieved progression-free survival (PFS) and showed a statistically significant and clinically meaningful improvement against palbociclib and…
04 Dec 23
ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin…